Radhika T, Gopalakrishnan S, Muthukumar R Sathish, Hari Rajeswary, Jeyaraman Madhan, Vijetha G
Department of Oral and Maxillofacial Pathology and Oral Microbiology, Thai Moogambigai Dental College and Hospital, Dr. M.G.R. Educational and Research Institute, Chennai, Tamil Nadu, India.
Department of Periodontics, Thai Moogambigai Dental College and Hospital, Dr. M.G.R. Educational and Research Institute, Chennai, Tamil Nadu, India.
J Oral Maxillofac Pathol. 2025 Jan-Mar;29(1):104-108. doi: 10.4103/jomfp.jomfp_39_25. Epub 2025 Mar 28.
Early detection of cancer is key to good prognosis and improved survival rate. Gastric cancer (GC) is fatal and presents with poor prognosis as it is usually diagnosed only at advanced stages. Saliva is emerging as a preferred diagnostic tool due to its advantages of being non-invasive, easy to collect, and cost-effective. Salivary microRNAs (miRNA) are more reliable due to their stability, resistance to degradation and its abundant involvement in cancer progression.
To estimate and validate the potential of salivary miRNA 301a in the diagnosis of Gastric cancer.
This Cross-sectional study comprised of 60 GC patients (Group I) and 60 normal controls (Group II). Fold change (FC) values of serum and salivary miRNA301a levels were estimated using the Real Time-Polymerisation Chain Reaction (RT-PCR) and compared between the study groups. Correlation between the serum and salivary miRNA301a levels was also evaluated. MiRNA301a levels were compared and correlated, with the clinical stage and histopathological grades of GC.
The mean FC of serum (Mean ± SD = 2.62 ± 0.75, Mean Rank = 90.5) and salivary (Mean ± SD = 2.03 ± 0.56, Mean Rank = 90.5) miRNA301a was significantly higher in Gastric cancer patients compared to controls (Mean ± SD = 0.99 ± 0.004, Mean Rank = 30.5). Salivary miRNA301a levels exhibited significant positive correlation with serum miRNA301a in gastric cancer patients (r = 0.941). The mean FC of serum and salivary microRNA 301a exhibited significant correlation with the clinical stages and histopathological grades of GC.
Salivary miRNA301a is a potential reliable diagnostic tool for early screening of Gastric cancer.
癌症的早期检测是良好预后和提高生存率的关键。胃癌（GC）是致命的，由于通常在晚期才被诊断出来，其预后较差。唾液因其具有非侵入性、易于收集和成本效益高的优点，正成为一种首选的诊断工具。唾液微小RNA（miRNA）因其稳定性、抗降解性以及在癌症进展中的大量参与而更可靠。
评估并验证唾液miRNA 301a在胃癌诊断中的潜力。
这项横断面研究包括60例胃癌患者（第一组）和60例正常对照（第二组）。使用实时聚合酶链反应（RT-PCR）估计血清和唾液miRNA301a水平的倍数变化（FC）值，并在研究组之间进行比较。还评估了血清和唾液miRNA301a水平之间的相关性。比较并关联了miRNA301a水平与胃癌的临床分期和组织病理学分级。
与对照组（均值±标准差=0.99±0.004，平均秩次=30.5）相比，胃癌患者血清（均值±标准差=2.62±0.75，平均秩次=90.5）和唾液（均值±标准差=2.03±0.56，平均秩次=90.5）miRNA301a的平均FC显著更高。胃癌患者唾液miRNA301a水平与血清miRNA301a呈显著正相关（r = 0.941）。血清和唾液微小RNA 301a的平均FC与胃癌的临床分期和组织病理学分级呈显著相关。
唾液miRNA301a是一种潜在可靠的胃癌早期筛查诊断工具。
